Gamida Cell Ltd. has run out of time and money. After failing to find a partner for allogeneic cell therapy Omisirge, the Israeli biotech is being acquired by Highbridge Capital Management, the company's principal lender.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
